Medicine and Dentistry
Cancer Therapy
50%
Neoplasm
50%
Malignant Neoplasm
50%
Gold Nanoparticle
50%
Antibody
50%
Endoglin
50%
Zirconium 89
50%
Inflammation
50%
Immune Checkpoint Inhibitor
50%
Non Small Cell Lung Cancer
50%
Nutritional Status
50%
Chemotherapy
35%
Conjugation
33%
Lung
28%
Biological Marker
21%
Plummer-Vinson Syndrome
20%
Analysis
16%
Radioactive Tracer
16%
Inductively Coupled Plasma Mass Spectrometry
16%
Oncology
14%
Therapeutic Procedure
14%
Immunoglobulin
14%
Diagnostic Error
12%
Deep Vein Thrombosis
12%
Laboratory Assessment
12%
Post-Analytical Phase
12%
Chemoradiation Therapy
10%
Quality of Life Assessment
10%
Drug Dose Reduction
10%
Lymphatic Drainage
10%
Lymphoscintigraphy
10%
In Vitro
8%
Injection
8%
Antibody Specificity
8%
Plasma
8%
Cancer Diagnosis
8%
Organ
8%
Combination Therapy
8%
Biodistribution
8%
Antibody Conjugate
8%
Nanoparticle
8%
Specific Tumor
8%
Association
7%
Patient
7%
Lung Cancer
7%
Retrospective Study
7%
Progression Free Survival
7%
Overall Survival
7%
Hospital
7%
Pharmacology, Toxicology and Pharmaceutical Science
Endoglin
100%
Neoplasm
100%
Antibody
64%
Gold Nanoparticle
50%
Radioisotope
50%
Yttrium 90
50%
Iodine-131
50%
Lutetium 177
50%
Iodine 124
50%
Rhenium 188
50%
Solid Malignant Neoplasm
50%
Malignant Neoplasm
50%
Iodine-125
50%
Complication
50%
Zirconium 89
50%
Tracer
28%
Toxicity
14%
Nanoparticle
7%
Monoclonal Antibody
7%
Biodistribution
7%
Non Small Cell Lung Cancer
7%
Incidence
7%
Side Effect
7%
Chloramine-T
7%
Bevacizumab
7%
Mouse
7%
Antibody Conjugate
7%
Monotherapy
7%
Progression Free Survival
7%
Immunology and Microbiology
Endoglin
100%
Deiodination
50%
Single Photon Emission Computed Tomography-Computed Tomography
50%
Monospecific Antibody
50%
Immunity
50%
Lung
50%
Cells
50%
Systemic Inflammation
50%
Conjugation
33%
Radioiodination
20%
Angiogenesis
10%
Bevacizumab
10%
Chloramine-T
10%
Isotope Labeling
10%
Intravenous Immunoglobulin
9%
Organ
8%
Time
8%
Mouse
8%
Contrast
8%
Antibody Specificity
8%
Antibody Conjugate
8%
Blood Plasma
8%
